Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego

Overview:

Chronic lymphocytic leukemia (CLL) is the most common hematologic leukemia among adults worldwide. Treatment for CLL has rapidly evolved away from chemoimmunotherapy to therapy that disrupts B-cell receptor signaling. Inhibitors of Bruton's tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) are now standard treatment pillars in the care of patients with CLL. Clinical trials continue to optimize these treatments in order to maximize efficacy, minimize toxicity, and address areas of unmet need.

Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego is a CME-certified webcast designed to rapidly disseminate new clinically relevant data, stressing the clinical relevance. This program will discuss the data from studies in CLL presented at the annual hematology meeting. Importantly, faculty will provide critical context that highlights clinical relevance.

Learning objectives:

• Describe how patient-specific characteristics and MRD have informed trial designs and risk stratification in recent studies conducted among patients with CLL
• Assess efficacy findings from studies evaluating novel strategies for patients with CLL in multiple lines of care
• Explain treatment-related adverse events and their management from recent trials conducted among patients with CLL
• Determine the ramifications of recent CLL trial results in the context of evolving treatment paradigms for these patients

Target audience:

This educational activity is directed toward hematologists, oncologists, NPs and nurses interested in the treatment of CLL.

Benefits of Attending:

• Learn about the most recent data from clinical trials evaluating treatment for CLL
• Get expert perspectives on the clinical relevance of data from recently presented clinical trials in CLL
• Hear discussions and debates on individualized care for CLL
• Learn strategies to prevent adverse events associated with treatment for CLL
• Discover emerging combination therapy strategies for the treatment of CLL

Hot Topics:

• Combination therapy for CLL
• Sequencing therapy for CLL
• Long-term outcomes data from key clinical trials

Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego 3:30 PM ET VIRTUAL
Time	Topic	Faculty
3:30 PM	Welcome, Faculty Introduction, and Pre-session Survey	Dr. Lamanna
3:40 PM	Abstract Presentations: Key Updates in CLL Care
	Treatment-Naïve CLL	Dr. Wierda
	Relapsed or Refractory CLL	Dr. Coombs
	New and Emerging Agents	Dr. Woyach
4:30 PM	Panel Discussion: Applying the Latest Data and Ongoing Trials to the Care of Your Patients with CLL	All Faculty. Moderated by Dr. Lamanna.
4:50 PM	Audience Q&A and Closing Thoughts	Dr. Lamanna
5:00 PM	Adjourn

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.